PULSAR in Cancer Treatment: Advancements in Breast Cancer Clinical Trials

In our last article, "Revolutionizing Cancer Treatment: The Promise of Stereotactic Body Radiation Therapy (SBRT)," we explored how SBRT is rewriting cancer care with precise, high-dose radiation in fewer sessions. Now, a next-level innovation is emerging: Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy (PULSAR), an approach being studied to adapt radiation based on tumor response, opening doors to smarter, more tailored treatments.

For breast cancer, traditionally tackled with surgery, chemo, and radiation, PULSAR-inspired strategies are sparking hope. By spacing out powerful radiation doses and pairing them with immunotherapy, researchers aim to rally the body's immune system to fight cancer harder. This could mean better tumor control with fewer side effects, especially for tough cases like triple-negative or metastatic disease.

This article covers how PULSAR concepts are being tested in breast cancer and their potential edge, key trials blending advanced radiation with immunotherapy (including who can join and where), the researchers driving this shift, and how patients and doctors can get involved.

PULSAR in Breast Cancer: Ongoing Research and Trials

Breast cancer hits millions worldwide, and while radiation remains a mainstay, PULSAR-inspired methods — like ultra-fractionated, adaptive stereotactic ablative radiotherapy (SABR) — bring a fresh twist. Spacing out doses gives tumors and tissues time to react biologically, potentially boosting control, cutting toxicity, and supercharging immunotherapy. Here are three trials putting these ideas to the test.

The KEYNOTE-A18 trial (NCT04105335), sponsored by Merck Sharp & Dohme LLC, is a Phase III study pairing standard radiation with pembrolizumab immunotherapy for high-risk, early-stage triple-negative breast cancer (TNBC) — comparing radiation alone vs. radiation plus pembrolizumab in patients with residual invasive cancer after neoadjuvant chemo. It enrolled around 1,600 patients and is active, though no longer recruiting, at multiple global sites.

The SABR-ATAC trial (NCT04892459), led by the University of Michigan Rogel Cancer Center, is a Phase II trial testing SABR — ultra-high-dose radiation — with atezolizumab immunotherapy in metastatic TNBC, hitting metastatic lesions with SABR to spark an immune response and combining it with atezolizumab to amplify the effect. It is recruiting an estimated 45 patients at the University of Michigan and partnering sites.

The I-SABR Breast trial (NCT04445844), run by the University of Texas Southwestern Medical Center, is a Phase II study blending SABR with durvalumab immunotherapy for oligometastatic breast cancer (1-5 metastases), targeting limited metastatic sites with precision SABR and durvalumab to boost the immune attack. It is recruiting an estimated 30 patients at UT Southwestern and collaborating centers.

Future Directions and Impact

PULSAR's vision — adapting radiation in real time — shines through in trials like these. By syncing SABR with immunotherapy, researchers hope to turn tumors into targets the immune system can't miss. Down the road, pairing this with targeted drugs (e.g., PARP inhibitors for TNBC) could offer a gentler, more potent alternative to traditional therapy.

PULSAR-inspired radiation is lighting a new path in breast cancer care. Trials like KEYNOTE-A18, SABR-ATAC, and I-SABR Breast are proving it's not just about blasting tumors — it's about teaching the body to fight back. Patients and doctors can join this wave now, with recruitment open at leading centers.

For those interested in participating or learning more, connecting with leading cancer centers and experts like Dr. Elisha Fredman is an essential first step. With new trials actively recruiting, now is the time to explore how adaptive radiation therapy can offer safer, more effective treatment options for breast cancer patients worldwide.

Questions or corrections? Reach out to Moshe Melamed at melamed.moshemmd@gmail.com.

How Second Opinion Oncology Can Help

At Second Opinion Oncology, we partner with top specialists behind trials like these. Seeking clarity on your plan? Fill out our contact form or explore our expert profiles to get started today.